Soliris (eculizumab) safely and effectively treated a 46-year-old man with atypical hemolytic uremic syndrome (aHUS) secondary to a scleroderma renal crisis —…
Teresa Carvalho, MS
Teresa holds her Master of Science in cell and molecular biology from Coimbra University, Portugal. She was a researcher and science communicator for several years at the Institute for Research and Innovation in Health in Oporto, Portugal. From 2013, she has held a fellowship working with Pulmonary Hypertension Europe as a patient advocate, social media/website manager, public relations officer, and translator. Her work has been focused on providing patients access to treatments, raising awareness for pulmonary hypertension, and promoting patient empowerment.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Teresa Carvalho, MS
CellCept (mycophenolate mofetil), an oral immunosuppressant used to prevent organ rejection, was effective in the treatment of a 10-year-old…
Soliris (eculizumab) shows effectiveness in treating patients with atypical hemolytic uremic syndrome (aHUS) both with and without severe and…
A booster dose of Moderna’s COVID-19 vaccine appears to have triggered an exaggerated immune response in a 38-year-old woman, leading…
Soliris (eculizumab) maintenance therapy administered every three weeks — instead of the biweekly standard regimen — was sufficient to…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases.